Spotlight on HER2-Positive Gastric Cancer: Using Biomarker Testing to Inform Treatment Decisions ...

Spotlight on HER2-Positive Gastric Cancer: Using Biomarker Testing to Inform Treatment Decisions  AstraZeneca

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line tr...

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer  AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps - AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps  AstraZeneca

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now av...

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery  AstraZeneca

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Ph...

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals  AstraZeneca

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5...

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs  AstraZeneca

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small ...

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer  AstraZeneca

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps ...

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps  AstraZeneca

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extra...

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH  AstraZeneca

Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patie...

Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial  AstraZeneca

Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longe...

Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer  AstraZeneca

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition - AstraZeneca

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition  AstraZeneca

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful impro...

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer  AstraZeneca

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation ...

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential  AstraZeneca

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantl...

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma  AstraZeneca

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell th...

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions  AstraZeneca

Exploring the genome to find novel targets for chronic diseases - AstraZeneca

Exploring the genome to find novel targets for chronic diseases  AstraZeneca

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumour...

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours  AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline - AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline  AstraZeneca

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement ...

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial  AstraZeneca

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Coun...

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Council and the Milner Therapeutics Institute at the University of Cambridge to accelerate drug discovery and further UK’s global genomics leadership  AstraZeneca

Acquisition of Icosavax Completed - AstraZeneca

Acquisition of Icosavax Completed  AstraZeneca

Soliris approved in China for the treatment of adults with refractory generalised myasthenia grav...

Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis  AstraZeneca

AstraZeneca’s IMFINZI™ (durvalumab) receives US FDA accelerated approval for previously treated p...

AstraZeneca’s IMFINZI™ (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer  AstraZeneca

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Sing...

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore  AstraZeneca

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters rep...

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters reports  CNN

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 20...

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio  AstraZeneca

AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com

AstraZeneca: acquires Modella AI to strengthen its oncology research  marketscreener.com

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful i...

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer  AstraZeneca

AstraZeneca Covid vaccine remained in use despite thousands of heart condition reports to drug re...

AstraZeneca Covid vaccine remained in use despite thousands of heart condition reports to drug regulator  GB News

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in d...

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial  AstraZeneca

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio - A...

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio  AstraZeneca

Koselugo showed statistically significant and clinically meaningful objective response rate vs. p...

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial  AstraZeneca

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of pro...

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes  AstraZeneca

FDA approves new medicine BRILINTA (ticagrelor) for use in the US - AstraZeneca

FDA approves new medicine BRILINTA (ticagrelor) for use in the US  AstraZeneca

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots - The...

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots  The Independent

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to...

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer  AstraZeneca

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung...

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo  AstraZeneca

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism...

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial  AstraZeneca

Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with ad...

Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial  AstraZeneca

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer ba...

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results  AstraZeneca

COVID-19 Vaccine AstraZeneca authorised for use in the EU - AstraZeneca

COVID-19 Vaccine AstraZeneca authorised for use in the EU  AstraZeneca

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure...

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19  AstraZeneca

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in ...

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants  AstraZeneca

Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma - AstraZeneca

Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma  AstraZeneca

Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder c...

Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer  AstraZeneca

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United S...

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites  AstraZeneca

CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pu...

CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease  AstraZeneca

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-I...

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer  AstraZeneca

AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstruc...

AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease  AstraZeneca

Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive a...

Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer  AstraZeneca

AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma - AstraZeneca

AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma  AstraZeneca

Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV eve...

Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk  AstraZeneca

AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral a...

AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease  AstraZeneca

Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer ...

Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer  AstraZeneca

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 - Astr...

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19  AstraZeneca

Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower...

Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants  AstraZeneca

Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexi...

Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas  AstraZeneca

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRC...

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer  AstraZeneca

ZURAMPIC® (lesinurad) approved by US FDA for patients with gout - AstraZeneca

ZURAMPIC® (lesinurad) approved by US FDA for patients with gout  AstraZeneca

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatme...

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer  AstraZeneca

Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refracto...

Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early  AstraZeneca

Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON tria...

Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer  AstraZeneca

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer - AstraZeneca

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer  AstraZeneca

FDA Advisory Committee recommends the approval of lesinurad for gout patients - AstraZeneca

FDA Advisory Committee recommends the approval of lesinurad for gout patients  AstraZeneca

Astrazeneca chooses LBT to develop automated microbial QC product - Cleanroom Technology

Astrazeneca chooses LBT to develop automated microbial QC product  Cleanroom Technology

Herzog & de Meuron unveils plans for drug research centre in Cambridge - Dezeen

Herzog & de Meuron unveils plans for drug research centre in Cambridge  Dezeen